

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

OVCAR-4

RRID:CVCL_1627

Type: Cell Line

Proper Citation

RRID:CVCL_1627

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1627

Proper Citation: RRID:CVCL_1627

Description: Cell line OVCAR-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:1348364](#), [PMID:2041050](#), [PMID:2307530](#), [PMID:3335022](#), [PMID:3930572](#), [PMID:6372095](#), [PMID:6385258](#), [PMID:7718330](#), [PMID:9041185](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:12080474](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23839242](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32612269](#), [PMID:35839778](#), [PMID:35918200](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCAR-4

Synonyms: OVCAR 4, NIH:OVCAR-4, NIH:OVCAR4, OVCAR.4, OVCAR4, Ovcara4

Cross References: BTO:BTO_0002561, CLO:CLO_0037096, EFO:EFO_0005442, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472889, BioSample:SAMN10987768, cancercellines:CVCL_1627, Cell_Model_Passport:SIDM00092, ChEMBL-Cells:ChEMBL3307517, ChEMBL-Targets:ChEMBL614051, Cosmic:688105, Cosmic:875860, Cosmic:897434, Cosmic:905990, Cosmic:974295, Cosmic:1044240, Cosmic:1092624, Cosmic:1175884, Cosmic:1305313, Cosmic:1312355, Cosmic:1436034, Cosmic:1998466, Cosmic-CLP:905990, DepMap:ACH-000617, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905990, GEO:GSM2174, GEO:GSM50220, GEO:GSM50284, GEO:GSM185137, GEO:GSM185138, GEO:GSM186442, GEO:GSM186443, GEO:GSM743475, GEO:GSM743494, GEO:GSM750829, GEO:GSM784572, GEO:GSM799364, GEO:GSM799427, GEO:GSM844669, GEO:GSM844670, GEO:GSM847107, GEO:GSM851935, GEO:GSM887484, GEO:GSM888565, GEO:GSM1153436, GEO:GSM1181279, GEO:GSM1181286, GEO:GSM1374801, GEO:GSM1670318, GEO:GSM2124646, IARC_TP53:21085, IARC_TP53:21126, IARC_TP53:30217, LiGeA:CCLE_876, LINCS_LDP:LCL-1697, Millipore:SCC258, NCI-DTP:OVCAR-4, PharmacDB:OVCAR4_1218_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1627, PubChem_Cell_line:CVCL_1627, SKY/M-FISH/CGH:2817, Wikidata:Q54937010

ID: CVCL_1627

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260829T235524+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-4.

No alerts have been found for OVCAR-4.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gendrau-Sanclemente N, et al. (2026) Sphingosine-1-Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis. International journal of cancer, 159(3), 768.

Saleh A, et al. (2026) CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. *Molecular oncology*.

Yamamoto TM, et al. (2026) Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. *Molecular cancer therapeutics*, 25(7), 1130.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Sun S, et al. (2026) CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. *Cell death & disease*, 17(1).

Gao Y, et al. (2026) DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis. *Biomedicines*, 14(4).

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Kimmel GJ, et al. (2026) Universal principles of cell population growth follow from local contact inhibition. *iScience*, 29(6), 115953.

Woodruff ER, et al. (2025) Ablation of hematopoietic stem cell derived adipocytes reduces tumor burden in syngeneic mouse models of high-grade serous carcinoma. *bioRxiv : the preprint server for biology*.

Cheng YY, et al. (2025) Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. *Cancer research communications*, 5(7), 1180.

Kenny HA, et al. (2025) Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. *Molecular cancer therapeutics*, 24(8), 1252.

Doro Pereira L, et al. (2025) PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma. *Cancer research communications*, 5(2), 339.

Hockings H, et al. (2025) Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control. *Cancer research*, 85(18), 3503.

Yuan S, et al. (2025) The protease ADAMTS5 controls ovarian cancer cell invasion, downstream of Rab25. *The FEBS journal*, 292(17), 4491.

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. *NPJ precision oncology*, 9(1), 3.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. *Cell reports*, 43(4), 114041.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Spiros AN, et al. (2024) RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. *bioRxiv : the preprint server for biology*.

Zhang Y, et al. (2024) Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma. *Cancer research communications*, 4(12), 3165.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.